



Antibiotic Therapy for Critically Ill Patients in the Age of COVID-19

Guest Editors:

Dr. Giancarlo Ceccarelli

Department of Public Health and
Infectious Diseases, Sapienza
University of Rome, Rome, Italy

Dr. Francesco Alessandri

Assistant Professor, Department
of Anesthesia, Critical Care and
Pain Medicine, Sapienza
University of Rome, Rome, Italy

Deadline for manuscript
submissions:

closed (30 November 2022)

Message from the Guest Editors

Dear Colleagues,

Treatment guidelines for community-acquired pneumonia recommend initial empiric antibiotic therapy for possible bacterial infection or co-infection, given that they often coexist and there are no clear diagnostic tests for determining if the pneumonia is solely due to a virus at the time of onset. On the other hand, treatment decisions must be weighed taking into account the rise of multidrug-resistant bacteria and complications associated with antibiotic use. Currently, there are no clear estimates on the incidence of bacterial co-infection in patients with COVID-19 and no clinical trials have been conducted on the use of empiric antibiotics in these patients. Some macrolides, teicoplanin and fluoroquinolones have been analyzed for their potential capacity to bind to SARS-CoV-2. We aimed to evaluate original articles and reviews to improve the knowledge on this interesting topic.

Dr. Giancarlo Ceccarelli

Dr. Francesco Alessandri

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi